Steven Roese has an extensive background with important and relevant experience and will work to bolster Frontida’s operational workflow. With his impressive history in the industry, Frontida is excited for Mr. Roese to confidently step into his responsibilities and be a leader within the company.
Featured Guest Speaker Wenyong Wang, PhD. 13th Portfolio Management & Pipeline Optimization for Generics Conference. October 1st, 2020 at 2:15pm (EST) on Marcus Evans Live+
Frontida BioPharm, Inc. Announces Highly Potent Compound Contract Manufacturing Suite to Support Existing Product Development and Manufacturing Capabilities
Highly potent compounds serve an increasingly significant role in numerous R&D landscapes and pharmaceutical intensive medical treatments; i.e. oncology, atrial fibrillation, osteoporosis.
Using our patented process, Frontida is able to reduce the amount of excipients and/or process steps used to build beads or controlled release granules.
The Wurster coating fluid beds located at Frontida's Aurora site come directly from what once proudly stood as a Fluid Air™ assembly and engineering site and Fluid Air’s PharmPro CMO operation.
FB-HRS, LLC Announces US FDA Clearance of IND Application to Initiate Clinical Trial for FBHRS001, a Treatment for Atrial Fibrillation
Atrial Fibrillation impacts a tremendous amount of people around the world and current treatment options are underwhelming due to negative side effects. FB–HRS, LLC has developed a treatment that may reduce those undesired consequences.
Frontida’s AdaptDose™ technology platform provides a tool that can eliminate the need to reformulate after Phase I and overcomes several technical hurdles in the development and scale up...
Frontida BioPharm, Inc. and Oncoceutics Inc. announced that the two companies have entered into a product development and commercialization agreement to further develop the finished product manufacturing process for ONC201...